Introduction: Lurasidone is an atypical antipsychotic agent approved in the European Union for the treatment of schizophrenia in adults and adolescents (13-17 years). Clinical trials have shown a generally favorable balance between efficacy and tolerability. Areas covered: This paper provides a review and commentary regarding the use of lurasidone in adults and adolescents with schizophrenia. The available information about efficacy, tolerability, dosing, and switching is analyzed, highlighting the strategies that may be most useful in real-world clinical practice. Virtual case studies, designed based on the authors' clinical experience with real-world patients, are provided. Expert opinion: Lurasidone is efficacious in adolescents and adults in a wide range of symptoms of schizophrenia. Choosing the right dose for each patient and combining lurasidone with other medications is key to treatment success. Lurasidone has proven effective both in adolescents and adults in treating the acute phase of schizophrenia and reducing the risk of relapse. It has shown a relatively favorable tolerability profile, with minimal effects on metabolic parameters and prolactin levels.

Lurasidone in adolescents and adults with schizophrenia. from clinical trials to real-world clinical practice / Fiorillo, Andrea; Cuomo, Alessandro; Sampogna, Gaia; Albert, Umberto; Calò, Paola; Cerveri, Giancarlo; De Filippis, Sergio; Masi, Gabriele; Pompili, Maurizio; Serafini, Gianluca; Vita, Antonio; Zuddas, Alessandro; Fagiolini, Andrea. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 23:16(2022), pp. 1801-1818. [10.1080/14656566.2022.2141568]

Lurasidone in adolescents and adults with schizophrenia. from clinical trials to real-world clinical practice

Cuomo, Alessandro
;
De Filippis, Sergio;Pompili, Maurizio;Serafini, Gianluca;
2022

Abstract

Introduction: Lurasidone is an atypical antipsychotic agent approved in the European Union for the treatment of schizophrenia in adults and adolescents (13-17 years). Clinical trials have shown a generally favorable balance between efficacy and tolerability. Areas covered: This paper provides a review and commentary regarding the use of lurasidone in adults and adolescents with schizophrenia. The available information about efficacy, tolerability, dosing, and switching is analyzed, highlighting the strategies that may be most useful in real-world clinical practice. Virtual case studies, designed based on the authors' clinical experience with real-world patients, are provided. Expert opinion: Lurasidone is efficacious in adolescents and adults in a wide range of symptoms of schizophrenia. Choosing the right dose for each patient and combining lurasidone with other medications is key to treatment success. Lurasidone has proven effective both in adolescents and adults in treating the acute phase of schizophrenia and reducing the risk of relapse. It has shown a relatively favorable tolerability profile, with minimal effects on metabolic parameters and prolactin levels.
2022
personalization; antipsychotic; lurasidone; schizophrenia; tolerability; treatment
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Lurasidone in adolescents and adults with schizophrenia. from clinical trials to real-world clinical practice / Fiorillo, Andrea; Cuomo, Alessandro; Sampogna, Gaia; Albert, Umberto; Calò, Paola; Cerveri, Giancarlo; De Filippis, Sergio; Masi, Gabriele; Pompili, Maurizio; Serafini, Gianluca; Vita, Antonio; Zuddas, Alessandro; Fagiolini, Andrea. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 23:16(2022), pp. 1801-1818. [10.1080/14656566.2022.2141568]
File allegati a questo prodotto
File Dimensione Formato  
Lurasidone in adolescents and adults with schizophrenia from clinical trials to real world clinical practice.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1 MB
Formato Adobe PDF
1 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1687314
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact